People

Oliver Eng, MD

City of Hope National Medical Center
- Fellowship

Rutgers University - Robert Wood Johnson Medical School
- Residency

Rutgers University - Robert Wood Johnson Medical School
- MD

Brown University
- ScB

Response to Comment on "Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy".
White MG, Eng OS. Response to Comment on "Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy". Br J Cancer. 2020 Dec 14.
PMID: 33318658

Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA): a phase 2 study evaluating an individualized treatment strategy for metastatic disease.
Catenacci DVT, Moya S, Lomnicki S, Chase LM, Peterson BF, Reizine N, Alpert L, Setia N, Xiao SY, Hart J, Siddiqui UD, Hogarth K, Eng OS, Turaga K, Roggin K, Posner MC, Chang P, Narula S, Rampurwala M, Ji Y, Karrison T, Liao CY, Polite BN, Kindler HL. Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA): a phase 2 study evaluating an individualized treatment strategy for metastatic disease. Cancer Discov. 2020 Nov 24.
PMID: 33234578

Response to: Comment on "Cancer Surgery During COVID-19 How We Move Forward".
Eng OS, Pawlik TM, Ejaz A. Response to: Comment on "Cancer Surgery During COVID-19 How We Move Forward". Ann Surg. 2020 Nov 17.
PMID: 33214441

Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy.
White MG, Schulte JJ, Xue L, Berger Y, Schuitevoerder D, Vining CC, Kindler HL, Husain A, Turaga KK, Eng OS. Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy. Br J Cancer. 2020 Oct 26.
PMID: 33100328

Complete Response in a Patient With Chemorefractory EGFR-Amplified, PD-L1-Positive Metastatic Gastric Cancer Treated By Dual Anti-EGFR and Anti-PD-1 Monoclonal Antibody Therapy.
Reizine N, Peterson B, Moya S, Wang Y, Tan YCYH, Eng OS, Bilimoria M, Lengyel E, Turaga K, Catenacci DVT. Complete Response in a Patient With Chemorefractory EGFR-Amplified, PD-L1-Positive Metastatic Gastric Cancer Treated By Dual Anti-EGFR and Anti-PD-1 Monoclonal Antibody Therapy. JCO Precis Oncol. 2020; 4.
PMID: 33215053

Novel Application of Iterative Hyperthermic Intraperitoneal Chemotherapy for Unresectable Peritoneal Metastases from High-Grade Appendiceal Ex-Goblet Adenocarcinoma.
Berger Y, Schuitevoerder D, Vining CC, Alpert L, Fenton E, Hindi E, Liao CY, Shergill A, Catenacci DVT, Polite BN, Eng OS, Turaga KK. Novel Application of Iterative Hyperthermic Intraperitoneal Chemotherapy for Unresectable Peritoneal Metastases from High-Grade Appendiceal Ex-Goblet Adenocarcinoma. Ann Surg Oncol. 2020 Sep 05.
PMID: 32892267

Apples to Oranges: Ethical Considerations in COVID-19 Surgical Recovery.
Eng OS, Tseng J, Ejaz A, Pawlik TM, Angelos P. Apples to Oranges: Ethical Considerations in COVID-19 Surgical Recovery. Ann Surg. 2020 08; 272(2):e52.
PMID: 32675494

Cancer Surgery During COVID-19: How We Move Forward.
Eng OS, Pawlik TM, Ejaz A. Cancer Surgery During COVID-19: How We Move Forward. Ann Surg. 2020 08; 272(2):e94-e95.
PMID: 32675508

Benchmarking Perioperative Outcomes of Cytoreductive Surgery for Cancer: Implications for Quality Measurement.
Liu JB, Schuitevoerder D, Vining CC, Berger Y, Turaga KK, Eng OS. Benchmarking Perioperative Outcomes of Cytoreductive Surgery for Cancer: Implications for Quality Measurement. Ann Surg Oncol. 2020 Dec; 27(13):5039-5046.
PMID: 32729047

Implications of Postoperative Complications for Survival After Cytoreductive Surgery and HIPEC: A Multi-Institutional Analysis of the US HIPEC Collaborative.
Gamboa AC, Lee RM, Turgeon MK, Zaidi MY, Kimbrough CW, Grotz TE, Leiting J, Fournier K, Lee AJ, Dineen SP, Powers BD, Veerapong J, Baumgartner JM, Clarke CN, Mogal H, Patel SH, Lee TC, Lambert LA, Hendrix RJ, Abbott DE, Pokrzywa C, Raoof M, Eng OS, Johnston FM, Greer J, Cloyd JM, Maithel SK, Staley CA. Implications of Postoperative Complications for Survival After Cytoreductive Surgery and HIPEC: A Multi-Institutional Analysis of the US HIPEC Collaborative. Ann Surg Oncol. 2020 Dec; 27(13):4980-4995.
PMID: 32696303

View All Publications